Shareholders that Lost Money on Myriad Genetics, Inc. (MYGN) Should Contact Levi & Korsinsky about Securities Fraud Investigation - MYGN
Portfolio Pulse from
Levi & Korsinsky has initiated a securities fraud investigation into Myriad Genetics, Inc. (MYGN) following UnitedHealth Group's decision to stop covering Myriad's GeneSight test starting January 2025.
November 13, 2024 | 10:00 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Myriad Genetics is under investigation for potential securities fraud after UnitedHealth announced it will stop covering the GeneSight test, which could impact Myriad's revenues.
The investigation by Levi & Korsinsky into Myriad Genetics for potential securities fraud is significant, as it follows UnitedHealth's decision to cease coverage of GeneSight. This could lead to a decrease in Myriad's revenues, negatively impacting its stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100